 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
With $3M Investment from Dental Insurer, Interleukin Explores New MDx Commercialization Strategy
July 03, 2012
With $3M Investment from Dental Insurer, Interleukin Explores New MDx Commercialization Strategy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Large Study, Interleukin Hopes to Drive Adoption, Reimbursement of Dx for Personalized Dental Care
April 11, 2012 / Pharmacogenomics Reporter - Interleukin Genetics Raises $12M in Private Placement
May 20, 2013 / GenomeWeb Daily News - Interleukin Genetics' Q4 Revenues Fall 41 Percent; Firm Cautions on Financial Resources
March 29, 2013 / GenomeWeb Daily News - Interleukin Genetics' Q3 Revenues Tumble 45 Percent
November 14, 2012 / GenomeWeb Daily News - MDx/CDx Focus: NeoGenomics Launches NeoType for CLL; Results for Interleukin's PST Test; and More
August 22, 2012 / Pharmacogenomics Reporter